New Delhi: Alembic Pharmaceuticals Ltd has reported a 21 percent year-on-year rise in consolidated net profit to Rs 185 crore for the quarter ended September 30, 2025. The company had posted a net profit of Rs 153 crore in the same period last year. Revenue from operations climbed to Rs 1,910 crore, up from Rs 1,648 crore in the corresponding quarter of the previous fiscal, PTI reported. The company’s US formulations business reported sales of Rs 639 crore, marking a 5% year-on-year increase compared to Rs 609 crore a year ago. Commenting on the results, Shaunak Amin MD, Alembic Pharmaceuticals Limited, said, Our Q2 performance reflects continued momentum in our core businesses and the disciplined execution. We have strengthened our presence across key markets while maintaining a sharp focus on profitability and operational excellence, delivering an overall growth of 16% and pre-R&D EBITDA margin of 26%. Our R&D investment, at around 10% of revenue, reflects our commitment to building a strong pipeline for future growth. We continue to focus on complex and high-value areas such as injectables, peptides, oral solids, and drug discovery. During the quarter, we completed the acquisition of Utility Therapeutics that provides a segway in to branded drugs in the US. Headquartered in India,Alembic Pharmaceuticals Limitedis a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.